Navigation Links
eResearchTechnology Names New Chief Financial Officer
Date:7/23/2008

PHILADELPHIA, July 23 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT or the Company), (Nasdaq: ERES), a leading provider of centralized ECG and eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device and related industries, announced today the appointment of Mr. Keith D. Schneck as Executive Vice President and Chief Financial Officer effective July 28th, 2008.

Mr. Schneck joins eRT with over 30 years of senior financial experience and executive management expertise in high growth companies and public accounting. He was previously Executive Vice President and Chief Financial Officer of Neoware, Inc., a publicly traded company before its acquisition in September 2007 by Hewlett-Packard, and he consulted in a transitional capacity until December 2007. Prior to Neoware, he served as Chief Financial Officer of T-Networks, a venture capital-funded start-up company that provides components to the telecommunications market. Mr. Schneck also has held positions as President and Chief Financial Officer for AM Communications and as Chief Operating Officer and Chief Financial Officer of Integrated Circuit Systems, also a publicly traded company. Mr. Schneck is a CPA with over 10 years of public accounting experience with KPMG LLP. During his career, Mr. Schneck has been responsible for a variety of financial and general management functions, including investor relations, finance, operations, business development, acquisitions and integration of acquired operations. He holds a BS from West Chester University and attended the Advanced Management Program at the Harvard Business School. In his position as Executive Vice President and Chief Financial Officer, Mr. Schneck will be responsible for financial reporting, corporate finance, investor relations and legal affairs for eRT.

"We are excited to have someone of Keith's expertise and talent join eRT," said Dr. Michael McKelvey, President and Chief Executive Officer of eRT. "His previous experience as a public company CFO and a Chief Operating Officer will be important as we continue to grow and implement our future strategy."

"I believe eRT is well positioned with a strong business model and a highly competent management team in an industry with attractive growth opportunities," commented Mr. Schneck. "I look forward to working with the team as we define and execute strategies that provide unique value to our customers, shareholders and employees."

About eResearchTechnology, Inc.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2008 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
2. eResearchTechnology Announces Resignation of its CFO
3. eResearchTechnology Reports First Quarter 2008 Results
4. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
5. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
6. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
7. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
8. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
9. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
10. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
11. HistoRx Names Bill Sullivan Senior Vice President, Diagnostic Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):